
FDA Fast Tracks Elticertinib for Previously Treated EGFR Exon 20 NSCLC
Key Takeaways
- Fast track status enables increased FDA interaction and potential rolling or priority review pathways if subsequent development milestones and evidentiary thresholds are met.
- EGFR exon 20 insertions remain a therapeutically challenging NSCLC subset due to altered kinase-domain conformation that can reduce sensitivity to earlier EGFR TKIs.
The designation supports development of elticertinib for patients with EGFR exon 20 insertion–mutated NSCLC progressing after platinum-based chemotherapy and amivantamab.
The FDA has granted fast track designation to investigational tyrosine kinase inhibitor (TKI) elticertinib (formerly STX-721; also known as PFL-721) for adults with locally advanced or metastatic EGFR exon 20 insertion (ex20ins)–mutated non–small cell lung cancer (NSCLC) whose disease has progressed following platinum-based chemotherapy and amivantamab (Rybrevant). The designation is supported by nonclinical findings and preliminary efficacy data from the ongoing phase 1/2 study (NCT06043817).1
Elticertinib is an oral, irreversible, highly selective investigational TKI targeting EGFR and ERBB2 (HER2) ex20ins mutations. The designation provides the company with additional opportunities for interaction with the FDA and potential eligibility for rolling and priority review if applicable criteria are met.
Elticertinib Targets a Challenging NSCLC Subtype
EGFR ex20ins mutations represent a distinct molecular subgroup of NSCLC that has historically presented treatment challenges. These alterations can affect the structure of the EGFR kinase domain, limiting the effectiveness of several earlier EGFR-targeted therapies.
Elticertinib is being developed to selectively inhibit EGFR and HER2 ex20ins mutations. Its oral administration and irreversible kinase inhibition represent an investigational approach for patients who have exhausted existing treatment options.
Marie-Andrée Gamache, pharma CEO of Laboratoires Pierre Fabre, emphasized the need for additional therapies in this population.
"This designation underscores the urgent need for new treatment options for patients with EGFR ex20ins-mutated NSCLC, who still face limited efficacy and significant tolerability challenges with currently available therapies," Gamache said in the news release.
Treatment Options Expand
Treatment options for EGFR ex20ins-mutated NSCLC have expanded in recent years. Amivantamab, a bispecific antibody targeting EGFR and MET, received FDA approval in combination with carboplatin and pemetrexed as first-line treatment for adults with locally advanced or metastatic disease. The approval was supported by the
The FDA also granted accelerated approval to oral
Elticertinib is being developed for a more heavily pretreated population, specifically patients whose disease has progressed following both platinum-based chemotherapy and amivantamab. Its potential role will depend on whether ongoing clinical development demonstrates meaningful antitumor activity and an acceptable safety profile in this setting.
FDA Fast Track Designation Supports Further Development
The company plans to continue advancing elticertinib through clinical development, with additional data needed to establish its potential as a treatment option for patients with previously treated EGFR ex20ins-mutated NSCLC.
Eric Ducournau, CEO of Laboratoires Pierre Fabre, described the designation as a milestone for the company's oncology research and development program.
"This fast-track designation is a first for Laboratoires Pierre Fabre, and a significant milestone that reflects the strength and maturity of our [research and development] capabilities in oncology," Ducournau said in the news release.
REFERENCES
Laboratoires Pierre Fabre: FDA fast track designation for elticertinib in NSCLC. News release. Laboratoires Pierre Fabre. November 17, 2026. Accessed November 18, 2026. https://tinyurl.com/3zj6m8kv
Girard N, Park K, Tang K, et al. Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR exon 20 insertion–mutated advanced non–small cell lung cancer (NSCLC). Ann Oncol. 2023;34(suppl 2):S1304. doi:10.1016/j.annonc.2023.10.060
ZEGFROVY (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations. News release. AstraZeneca. October 22, 2026. Accessed November 18, 2026. https://tinyurl.com/4b6j58vt
Related to this article








